Novo, Lilly shares rise as Trump obesity drug deal nears
PositiveFinancial Markets

Novo, Lilly shares rise as Trump obesity drug deal nears
Shares of Novo Nordisk and Lilly have surged as a deal for a new obesity drug approaches, signaling a significant advancement in the fight against obesity. This is important because obesity is a growing health crisis, and effective treatments can improve the quality of life for millions. The collaboration could lead to innovative solutions and increased market competition, benefiting patients and the healthcare industry.
— via World Pulse Now AI Editorial System






